Jack Wallace
Stock Analyst at Guggenheim
(2.22)
# 2,600
Out of 4,835 analysts
19
Total ratings
52.63%
Success rate
6.14%
Average return
Main Sectors:
Stocks Rated by Jack Wallace
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VEEV Veeva Systems | Maintains: Buy | $233 → $249 | $242.78 | +2.56% | 4 | Oct 1, 2024 | |
| HIMS Hims & Hers Health | Maintains: Buy | $15 → $17 | $64.65 | -73.70% | 4 | Feb 27, 2024 | |
| HCAT Health Catalyst | Upgrades: Buy | $14 | $4.06 | +244.83% | 3 | Jan 26, 2024 | |
| IQV IQVIA Holdings | Maintains: Buy | $253 → $220 | $142.82 | +54.04% | 1 | Nov 3, 2023 | |
| PHR Phreesia | Maintains: Buy | $35 → $40 | $25.40 | +57.48% | 5 | Mar 29, 2023 | |
| AMWL American Well | Reiterates: Buy | $100 | $7.46 | +1,240.48% | 1 | Mar 15, 2023 | |
| PINC Premier | Initiates: Neutral | n/a | $23.12 | - | 1 | Apr 14, 2022 |
Veeva Systems
Oct 1, 2024
Maintains: Buy
Price Target: $233 → $249
Current: $242.78
Upside: +2.56%
Hims & Hers Health
Feb 27, 2024
Maintains: Buy
Price Target: $15 → $17
Current: $64.65
Upside: -73.70%
Health Catalyst
Jan 26, 2024
Upgrades: Buy
Price Target: $14
Current: $4.06
Upside: +244.83%
IQVIA Holdings
Nov 3, 2023
Maintains: Buy
Price Target: $253 → $220
Current: $142.82
Upside: +54.04%
Phreesia
Mar 29, 2023
Maintains: Buy
Price Target: $35 → $40
Current: $25.40
Upside: +57.48%
American Well
Mar 15, 2023
Reiterates: Buy
Price Target: $100
Current: $7.46
Upside: +1,240.48%
Premier
Apr 14, 2022
Initiates: Neutral
Price Target: n/a
Current: $23.12
Upside: -